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Diabetes is a chronic, progressively worsening disease asso-ciated with a variety of microvascular and macrovascular
complications. Cardiovascular disease (CVD) is the main cause
of death in these patients.1,2 During the past decade, numerous
drugs have been introduced for the treatment of type 2 diabetes
that, used in monotherapy or in combination therapy, are
effective in lowering blood glucose to achieve glycemic goals
and in reducing diabetes-related end-organ disease.
Two such drugs, rosiglitazone and pioglitazone, belong to
the class called thiazolidinediones (TZDs).3 Troglitazone, the
first agent of this class to be approved, was effective in
controlling glycemia but was removed from the market
because of serious liver toxicity. Both rosiglitazone and
pioglitazone are indicated either as monotherapy or in com-
bination with a sulfonylurea, metformin, or insulin when diet,
exercise, and a single agent do not result in adequate
glycemic control4 (package insert Avandia [rosiglitazone
maleate; GlaxoSmithKline] and Actos5 [pioglitazone hydro-
chloride; Takeda Pharmaceuticals]). In addition to lowering
blood glucose, both drugs may benefit cardiovascular param-
eters, such as lipids, blood pressure, inflammatory biomark-
ers, endothelial function, and fibrinolytic status.6,7
These beneficial effects of TZDs on glycemia and cardio-
vascular risk factors have made them attractive agents in
patients with type 2 diabetes who are at high risk for CVD.
There is a growing recognition, however, that edema can
occur in patients treated with either drug. Because people
with diabetes are at increased risk for CVD and many have
preexisting heart disease, the edema that sometimes accom-
panies the use of a TZD can be cause for concern, as it may
be a harbinger or sign of congestive heart failure (CHF). An
analysis of Medicare beneficiaries hospitalized with the
diagnosis of diabetes and CHF indicated that the number of
these patients discharged on TZDs had increased from 7.2%
to 16.2% over a 3-year period.8 As the number of patients
taking these drugs to control glycemia increases, practitioners
should be aware of the safety profile of TZDs in patients with
and without underlying heart disease.
The clinical trials evaluating the safety and efficacy of both
TZD drugs excluded subjects in New York Heart Association
(NYHA) class III or IV cardiac functional status. In other words,
patients with moderate to severe limitation of physical activity
due to symptoms of angina or CHF during daily activities or at
rest were not enrolled. In addition, although these trials did
include patients with class I or II NYHA cardiac status, it is not
clear exactly what percentage of the total patients studied fell
into these latter two categories. Also, clinicians or investigators
may have knowingly excluded patients with significant under-
lying heart disease. Regardless, there were very few serious
cardiac events in the short-term clinical trial data submitted with
the new drug applications for either TZD.
Risk factors for CHF, such as coronary artery disease and
hypertension, frequently occur in patients with diabetes.1,9
These risk factors act synergistically in diabetes to increase
the risk for CHF. Diabetes also may affect cardiac structure
and systolic or diastolic function, independent of other
established risk factors for CHF, as a result of diabetic
cardiomyopathy.10–12 Therefore, diabetes is a strong and
independent risk factor for CHF. For example, an analysis of
a large number (n9591) of registrants with type 2 diabetes
in the Kaiser Permanente Northwest Division demonstrated
that CHF was present in 11.8% of diabetic subjects at
baseline, and an additional 7.7% developed CHF over a
30-month follow-up period.13 Clinicians should be cognizant
that CHF or left ventricular dysfunction (systolic or diastolic)
may be present at the time TZDs are first prescribed or may
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occur over time during TZD treatment. Patients with type 2
diabetes who have significant underlying asymptomatic heart
disease may also be prescribed these drugs, even though their
safety in such patients has not been fully established.
The package inserts for both rosiglitazone and pioglitazone
indicate that patients with more advanced heart disease (class
III or IV) were excluded in premarketing clinical trials, and
hence, these drugs are not recommended in such patients. At
present, there are no guidelines on the use of TZDs in patients
with diabetes who have any degree of heart disease or for
those already on a TZD who develop CHF. Because edema is
a more frequent side effect of TZD therapy and by itself is
often a perplexing clinical dilemma with multiple causes,14
clinicians may need guidance when edema (or unexpected
weight gain) is encountered in a patient on a TZD. For these
reasons, the American Diabetes Association and the Ameri-
can Heart Association assembled a workgroup to evaluate the
use of TZDs in patients with preexisting heart disease and in
those who develop edema or unexpected weight gain during
the course of TZD therapy. This Statement is a summary of
the workgroup’s findings and recommendations.
Development of Weight Gain and TZDs
In a 52-week study comparing rosiglitazone to a sulfonylurea
(glyburide, median dose 7.5 mg/d), a mean weight gain of 1.9
kg was observed in both the sulfonylurea group and the
rosiglitazone group at the 4-mg daily dose, and a 2.9-kg
weight gain was observed at the rosiglitazone 8-mg daily
dose.4 When coadministered with a sulfonylurea in a 26-week
study, rosiglitazone at 4 mg/d was associated with a 1.8-kg
weight gain compared with sulfonylurea alone. Similar
weight gain has been observed when rosiglitazone is added to
metformin. When added to insulin therapy, however, weight
gain may be more dramatic. After 6 months of treatment,
weight gains of 4.1 kg and 5.4 kg were encountered when
rosiglitazone, at the 4-mg and 8-mg daily doses, respectively,
was added to insulin (mean dose 70 U/d), compared with a
weight gain of 1 kg in patients treated with insulin alone.4
Similar increases have been observed with pioglitazone,
either as monotherapy or in combination with other hypogly-
cemic therapies, although the duration of treatment was not
identical.15 Compared with placebo, pioglitazone mono-
therapy caused median weight gains of 0.9, 1.0, and 2.6 kg at
the 15-, 30-, and 45-mg daily doses, respectively.5 Median
weight gains of 2.3 and 3.6 kg occurred when pioglitazone at
15 and 30 mg daily was added to insulin. In contrast to trials
with rosiglitazone, which included changes in weight gain at
rosiglitazone’s highest recommended daily dose (8 mg), the
clinical trial data submitted to the US Food and Drug
Administration in support of pioglitazone did not include data
on weight gain at its highest recommended daily dose of 45
mg when coadministered with sulfonylurea, metformin, or
insulin, although these data have recently been cited. Thus,
the weight gain associated with TZD use seems to be dose
dependent, although in one 4-month randomized open-label
trial, similar increases in body weight (2 kg) were seen
across the entire dose ranges of rosiglitazone (2 to 8 mg/d)
and pioglitazone (15 to 45 mg/d).16
The weight gain associated with the use of TZDs is
probably due to several interacting factors. In general, im-
provement in glycemic control with decreased glycosuria and
caloric retention may result in increased weight. Several
studies have shown that the weight gain with TZDs may be
associated with an increase in subcutaneous adipose tissue
and a concomitant decrease in visceral fat; although subcu-
taneous fat area increases, visceral fat area and the ratio of
visceral to subcutaneous fat decrease.17,18 This change in fat
distribution may explain in part the improvement in glycemic
control despite an overall increase in body weight.19 A
decrease in leptin levels and an increase in appetite have been
seen with troglitazone treatment20; however, it is not clear if
weight gain associated with rosiglitazone or pioglitazone can
be attributed to this effect. Fluid retention, of course, is
another potential cause of increased body weight. TZDs,
whether administered alone or in combination with met-
formin, sulfonylurea, or insulin, are often accompanied by an
increase in plasma volume. In healthy volunteers who re-
ceived rosiglitazone (8 mg once daily) for 8 weeks, there was
a small but statistically significant increase in mean plasma
volume of 1.8 mL/kg compared with placebo.4 For rosigli-
tazone, the fall in hemoglobin ranged from 0.8 to 1.1 g/dL
(with a similar fall in hematocrit ranging from 2.3% to 3.6%)
relative to whether the drug was used as monotherapy or
combination with other oral agents or insulin.4 Similar
decreases in hemoglobin have been observed with pioglita-
zone.5 These changes in weight gain and blood profile are
usually observed during the first weeks of therapy and plateau
thereafter. No clinically significant changes in other cellular
components of blood have been seen, nor has an increase in
red blood cell turnover been demonstrated, which suggests
that TZDs have no effect on erythropoiesis.21,22 Thus, the
changes in hemoglobin and hematocrit may reflect, in part,
hemodilution resulting from increased plasma volume. With
an increase in plasma volume, mild to moderate edema and
CHF might be anticipated side effects of treatment with these
drugs, dependent to some degree on whether TZDs are used
in conjunction with insulin (see below) and on the presence
and degree of concomitant heart disease.
Development of Edema and TZDs
When used as monotherapy, the incidence of pedal edema
ranges from 3% to 5% for each of the TZDs. The incidence
is greater when the drugs are used in combination with other
glucose-lowering agents. In the US placebo-controlled trials,
edema occurred in 4.8% of subjects on pioglitazone mono-
therapy, versus 1.2% on placebo.23 When pioglitazone was
combined with sulfonylureas, edema was noted in 7.5% of
patients compared with 2.1% on sulfonylureas alone. Edema
was seen in 6.0% of patients on a pioglitazone/metformin
combination versus 2.5% on metformin alone.24,25 In double-
blind trials with rosiglitazone, the incidence of edema was
4.8% in the rosiglitazone group compared with 1.3% on
placebo. When combined with metformin or sulfonylurea,
edema was observed in 3% to 4% of patients compared with
1.1% to 2.2% on either comparator drug alone.4 These data
suggest that edema is a side effect of each of the TZD drugs
to a similar degree, either when used as monotherapy or when
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combined with other oral diabetes agents. Edema is more
common when the TZD is used in combination therapy.
Practitioners are most likely to see edema as a consequence
of TZD therapy when either of the TZDs is used in combi-
nation with insulin. For example, rosiglitazone 4 or 8 mg per
day in combination with insulin was associated with a 13.1%
and 16.2% incidence of edema, respectively, compared with
4.7% in those taking insulin alone.26 Pioglitazone at 15 mg or
30 mg daily in combination with insulin resulted in a
combined 15.3% incidence of edema, compared with 7.0%
for insulin alone.27 Therefore, the incidence of edema is
higher when either of the TZDs is combined with insulin
compared with other oral hypoglycemic agents. It should also
be noted, however, that edema occurs more commonly with
insulin monotherapy than with sulfonylureas or metformin
when either is prescribed alone or in combination. Type 2
diabetes patients on insulin usually have had diabetes for
many years and thus are likely to be older and have a greater
prevalence of hypertension, left ventricular hypertrophy, and
a history of coronary artery disease—all conditions more
likely to be associated with edema. Indeed, among 166
diabetic patients treated with TZD who had numerous comor-
bid conditions and were monitored at a Veterans Affairs
Clinic over 14 months, edema developed in 18.1%. Baseline
azotemia, prior CHF, and coronary artery disease were
common in this group.28 The prevalence of background CHF
in patients treated with insulin alone may also be higher than
in patients not receiving insulin (2.5% in some rosiglitazone
trials),28,29 thereby contributing to a higher incidence of
edema when a TZD is added to insulin compared with other
glucose-lowering agents. Although the TZDs have not been
compared with each other at equipotent dosages, the inci-
dence of edema was similar when either drug was combined
with other hypoglycemic drugs in a short-term, nonrandom-
ized clinical study.16
Pathogenesis of Edema With TZD Use
The reasons for fluid retention and peripheral edema with
TZD use are not fully understood and are likely to be
multifactorial. The increase in plasma volume related to
TZDs has already been cited and may result from a reduction
in renal excretion of sodium and an increase in sodium and
free water retention.30 TZDs may interact synergistically with
insulin to cause arterial vasodilatation, leading to sodium
reabsorption with a subsequent increase in extracellular
volume, and thereby resulting in pedal edema. Increased
sympathetic nervous system activity,31 altered interstitial ion
transport,32 alterations in endothelial permeability,33 and per-
oxisome proliferator–activated receptor-–mediated expres-
sion of vascular permeability growth factor34 represent other
possible mechanisms for edema with these agents.
TZDs and CHF
In clinical trials using TZDs, CHF was not frequently
encountered. The incidence of CHF was 1% for rosiglita-
zone monotherapy or when rosiglitazone was added to
sulfonylurea or metformin, and was similar to that observed
during treatment with a placebo.4 When rosiglitazone at either
4 or 8 mg/d was added to insulin therapy, however, CHF
increased to 2% and 3% of the study population, respectively,
compared with 1% in the group treated with insulin alone.4 It
is important to note that preexisting microvascular and
cardiovascular comorbidity was more prevalent in those
clinical trials in which rosiglitazone was added to insulin
therapy than in those trials in which rosiglitazone was either
used alone and compared with placebo or combined with
metformin or sulfonylureas. The patients who developed
CHF on rosiglitazone plus insulin were also older and had
diabetes of longer duration.
The data on pioglitazone are somewhat similar. In a
placebo-controlled trial,5 2 of 191 patients (1.1%) receiving
15 mg pioglitazone plus insulin and 2 of 188 (1.1%) patients
receiving pioglitazone (30 mg) plus insulin developed CHF,
compared with none of the 187 patients receiving insulin
alone. All 4 of these patients had underlying coronary artery
disease.
The rosiglitazone and pioglitazone trials are not entirely
comparable, as the rosiglitazone maximum recommended
daily dose (8 mg/d) was evaluated in the rosiglitazone trials,
whereas pioglitazone was not evaluated at its highest dose of
45 mg/d when combined with other hypoglycemic agents.
Also, here too, the duration of treatment differed apprecia-
tively—26 weeks with rosiglitazone and 16 weeks with
pioglitazone. It is unlikely, however, that the drugs differ with
regard to the risk of CHF, as they incur similar degrees of
volume expansion. In summary, the incidence of CHF in
TZD-treated patients is very low but is definitely higher in
patients already treated with insulin who receive higher doses
of the TZD and who have other risk factors for CHF.
Pathogenesis of CHF With TZD Use
The peripheral edema or CHF associated with the use of the
drugs would suggest that an increase in plasma volume is the
main culprit, either alone or superimposed on preexisting
heart disease. The effect of TZDs on cardiac structure and
function has been reported in a few studies. An increase in
left ventricular mass as an adaptation to volume expansion
has been noted in animals given long-term troglitazone
administration at doses exceeding those used in the clinical
setting.35 In clinical trials, however, treatment with troglita-
zone did not result in any significant change in left ventricular
mass after 48 weeks of observation.36 In a recent study,37 203
patients were randomly assigned to either rosiglitazone (4 mg
BID) or glyburide (mean dose 10.5 mg QD and titrated to
20 mg/d). An echocardiogram was performed on 118 of
these patients before and 52 weeks after treatment to assess
left ventricular mass index, ejection fraction, and end-diastol-
ic volume. Neither drug produced an increase in left ventric-
ular mass index that exceeded one standard deviation or a
decrease in left ventricular ejection fraction in either group,
and both drugs were associated with clinically insignificant
increases in left ventricular end-diastolic volume. Fluid re-
tention resulting in increased plasma volume was thought to
explain the small but insignificant increase in left ventricular
end-diastolic volume seen with rosiglitazone in this study.
Similarly, a preliminary report38 using pioglitazone evaluated
cardiac mass and function in patients with type 2 diabetes in
a long-term, open-label study. Pioglitazone to a maximum
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dose of 60 mg QD for up to 48 weeks had no adverse effect
on cardiac structure and function as evaluated by echocardi-
ography. Unfortunately, there are no published data on
cardiac structure and function in patients on long-term TZD
therapy who have preexisting left ventricular dysfunction or
who develop an acute coronary event while receiving TZD
therapy. There are, however, animal studies suggesting that
TZDs may have a beneficial effect on left ventricular remod-
eling and function after ischemic injury.39,40
The effect of rosiglitazone on the left ventricular response
to ischemia has been assessed in an ischemia-reperfusion
model in experimental animals. When rosiglitazone was
administered immediately before an episode of ischemia, the
full recovery of left ventricular function after reperfusion was
more rapid compared with control animals.39 A recent study
has also demonstrated that pioglitazone improved left ven-
tricular remodeling and partially normalized systolic function
in mice after extensive anterior myocardial function.40 These
cardioprotective effects of TZDs are independent of glucose
lowering and may be due to antioxidant, antiinflammatory, or
glucometabolic properties of the drugs. Hence, it is possible
that TZDs may have direct effects on cardiac muscle that
prevent heart failure in the setting of acute ischemia.
Clinical Practice Experience With TZDs
Epidemiological studies have also examined the relationship
between TZDs and the risk of CHF. Delea and coworkers,41
in a retrospective, observational study of health insurance
claims, determined the risk of heart failure among diabetic
patients prescribed TZDs over a 5-year period (1996–2001),
with a mean follow-up period of 8.5 months. The risk of heart
failure was 4.5% in the groups exposed to TZDs and 2.6% in
those not exposed to a TZD. The increased risk (hazard ratio
of 1.6, P0.001) persisted after adjustment for potential
confounders, including age, history of complications of dia-
betes, risk factors for CHF, and use of various medications for
diabetes or CHF. Increased risk was also associated with
advanced age, history of coronary artery disease, diabetes-
related end-organ disease, and the use of angiotensin-
converting enzyme inhibitors, -blockers, or insulin.
In another preliminary report by Karter and coworkers42
using the Kaiser Permanente Northern California Registry,
the incidence of CHF was evaluated in27 000 patients with
diabetes not previously treated with oral hypoglycemic drugs
who were prescribed pioglitazone or other glucose-lowering
drugs in a nonrandomized manner and monitored for 1.5
years in a prospective, observational cohort study. Overall, 74
(0.2%) of the 24 973 subjects without prior history of CHF
experienced a first episode of CHF, and 69 (3.5%) of the 1964
patients with a history of CHF experienced a subsequent bout.
Compared with patients given a sulfonylurea, the hazard ratio
for CHF in patients receiving pioglitazone was 1.8. Patients
in this study treated with pioglitazones or insulin, either alone
or in combination, had a higher risk profile for CHF before
initiation of glucose-lowering therapy. Such patients also
were more likely to have diabetes of longer duration, a history
of hypertension, or microalbuminuria or to be treated for
hyperlipidemia. When adjusted for risk factors associated
with heart failure as well as determinants of diabetes severity
and socioeconomic status, the TZD hazard ratio decreased to
1.2 and was similar to that of insulin combined with other oral
hypoglycemic agents. The risk for recurrent heart failure in
those subjects in whom a diagnosis of CHF had been made in
the 5 years before implementation of glucose-lowering ther-
apy was not significantly elevated in the pioglitazone group
or in the group treated with insulin in combination with either
metformin or sulfonylurea, compared with those given a
sulfonylurea. These authors concluded that the risk profiles of
patients initiated on pioglitazone therapy (or on insulin)
identified them as being at increased risk for CHF before
TZD treatment was begun and that there appeared to be no
significant increase in CHF with pioglitazone treatment after
adjusting for preexisting disease severity.
This Karter study suggests that despite the common occur-
rence of edema with TZDs, the excess risk of CHF attribut-
able to the TZD itself in relative terms is very small. A report
from the Cleveland Clinic43 evaluated the occurrence and
characteristics of fluid retention in an observational analysis
of patients with type 2 diabetes, class I to III CHF, and a
documented ejection fraction of45% who were treated with
troglitazone, rosiglitazone, or pioglitazone over a 2-year
period. Of the 111 subjects, 19 (17.1%) developed fluid
retention, defined as a weight gain of 10 lb associated with
peripheral edema. Of these 19, 6 (5.4%) manifested worsen-
ing jugular venous distension, and 2 experienced pulmonary
edema. Fluid retention was related to female gender and
concomitant insulin use but not related to degree of underly-
ing CHF severity. Although not a prospective study, this
study suggested that despite posing a “significant” risk for
edema, TZDs could be used in diabetic patients with “stable”
CHF as long as they are closely monitored for signs of fluid
overload. Several clinical trials are underway that will help
define the level of risk for CHF in TZD-treated patients.
Many of these prospective controlled studies have predeter-
mined cardiovascular end points and are being carried out in
subjects with impaired glucose tolerance or type 2 diabetes
with and without underlying heart disease.
Despite the low incidence of CHF in clinical trials and
cohort studies, there have been a small number of case reports
that have described CHF in these patients treated with
TZDs.28,44–48 These reports are noteworthy inasmuch as
TZDs were used in patients with diabetes and a wide
spectrum of background cardiovascular conditions, and this
experience could illustrate what may be encountered in
clinical practice. In these reports, CHF occurred in patients
with either depressed or normal systolic function and was
usually encountered when the TZD was used in combination
with insulin. In most cases, the onset of CHF was preceded by
the appearance of edema after initiation of TZD treatment.
CHF in the setting of normal systolic function may be
particularly common in the setting of diabetes, as diabetes
may decrease left ventricular compliance even in the absence
of hypertension and ischemic heart disease. Considering the
volume sensitivity of such patients, a new diagnosis of CHF
in a patient recently begun on TZDs could be attributable to
the increase in plasma volume unmasking previously asymp-
tomatic and unrecognized diastolic dysfunction. These case
reports indicate that significant CHF can occur and may be
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directly attributable to TZD therapy. Although warnings exist
on the use of TZDs in patients with significant heart disease,
clinicians should be aware that CHF can sometimes occur in
the patient with diabetes who otherwise appears to be at low
risk for such adverse events. Despite these reports and the
possibility of underreporting of drug-related adverse events
or side effects, the risk of CHF seems to be very low, given
the number of patients treated with TZDs.
Recommendations
On consideration of the above information, the workgroup
recommends the following (see the Figure):
Before TZD treatment, the physician should:
A. Ascertain whether the patient has underlying cardiac
disease—ie, previous myocardial infarction or other evi-
dence of coronary artery disease, prior episodes of CHF,
or significant aortic or mitral valve disease.
B. Note whether the patient is taking any drugs associated
with fluid retention (eg, vasodilators, nonsteroidal antiin-
flammatory drugs) or pedal edema (eg, calcium channel–
blocking drugs).
C. Evaluate the pathogenesis of edema that may be already
present to be sure that CHF is not present at the time the
TZD is prescribed. The presence of edema, when not
caused by CHF, is not a contraindication for TZD use.
However, if present, the degree of edema should be
monitored carefully during TZD administration.
D. Determine whether the patient has any shortness of
breath, particularly with exertion, that might be due to
cardiac or other causes (eg, asthma, chronic obstructive
pulmonary disease, obesity) so that an adequate assess-
ment of baseline symptoms is established. Patients with
these symptoms should be monitored carefully, partic-
ularly in the first 3 months of TZD treatment.
E. Review most recent ECG, if indicated. The ECG may
show a clinically silent myocardial infarction or left
ventricular hypertrophy—two conditions that are risk
factors for CHF.
F. Instruct the patient before initiation of TZD to report any
new sign or symptom during the course of treatment, such
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as weight gain 3 kg, pedal edema (particularly if the
onset is acute and the amount progresses rapidly), short-
ness of breath, or fatigue without other apparent cause.
Use of TZDs in Patients With Diabetes and
Without Symptomatic Heart Disease
● In patients without established heart disease, both piogli-
tazone and rosiglitazone should be prescribed according to
the package insert guidelines for each drug. It should be
recognized that weight gain and/or edema will be encoun-
tered more often in patients on concomitant insulin
treatment.
● When a TZD is prescribed to patients who do not have
established heart disease but have 1 or more risk factors for
CHF (see the Table), one should consider starting with low
doses (eg, rosiglitazone 4 mg QD or pioglitazone 15 mg
QD) and increase the dosage gradually as required to
optimize glycemic control, while observing for any signs of
excessive weight gain, peripheral edema, or CHF.
● In patients who do not have symptoms or signs of CHF but
are known to have a depressed ejection fraction (eg,
40%), TZDs may be used at the lower dosage range of
each drug. Dosages can be adjusted gradually after several
months of treatment to optimize glycemic control with
careful observation for edema and symptoms and signs of
CHF. It is not uncommon for patients with diabetes without
symptomatic heart disease to have had determinations of
LV function with noninvasive cardiac testing in the course
of screening for coronary artery disease or as part of a
preoperative evaluation for surgical procedures. This rec-
ommendation is presented because patients with depressed
cardiac function are at higher risk for CHF due to fluid
retention from any cause, despite the absence of cardiac
symptoms. The results of ongoing clinical trials will help to
determine the safety of TZD use in these patients.
Use of TZDs in Patients With Diabetes and
Symptomatic Heart Disease
● In patients with class I or II NYHA CHF categories, TZDs
may be used cautiously, with initiation of treatment at the
lower dosage of each drug (eg, rosiglitazone 2 mg QD or
pioglitazone 15 mg QD). Observation with gradual dose
escalation is warranted to identify weight gain, edema, or
an exacerbation of CHF. One should allow more time than
usual to achieve a target Hgb A1C in these patients. Ongoing
clinical trials will help to establish the safety of TZD use in
these patients.
● In patients with symptoms and signs of NYHA class III or
IV CHF, TZDs should not be used at this time.
Monitoring Patients on TZD Therapy
● Once on TZDs, patients should be instructed to monitor for
weight gain or the presence of pedal edema. If edema
develops, particularly within the first few months of TZD
therapy, the physician should determine whether CHF is
present. Symptoms suggestive of CHF may include orthop-
nea, paroxysmal nocturnal dyspnea, unexplained cough or
fatigue, or pedal edema. A physical examination should be
performed to determine if there are signs of CHF (eg,
jugular venous distention, an S3 gallop, pulmonary rales).
Pedal edema in conjunction with any of these symptoms or
signs may indicate that the edema is a manifestation of
CHF even in the absence of a prior history of heart disease.
A noninvasive cardiac evaluation including an ECG and
echocardiogram should also be performed, and brain natri-
uretic peptide measurement may also be helpful. Even in
the absence of prior cardiac disease, such an evaluation
may reveal changes in cardiac function that have occurred
during the course of TZD treatment. An exercise tolerance
test or stress imaging (echo or perfusion) study may also be
indicated if any of the symptoms are thought to be ischemic
in origin.
● If edema occurs and CHF is not present during TZD
therapy, other causes of the edema should be investigated
before attributing it to the TZD. For example, other drugs
associated with pedal edema or venous insufficiency may
be responsible. The presence of edema with prior protein-
uria may indicate nephrotic syndrome. Diuretics may be
prescribed or the dose of diuretic increased (when pre-
scribed as an antihypertensive agent) for those patients who
do not tolerate pedal edema, although the effectiveness of
diuretics in TZD-related edema may be variable. Several
studies have suggested that the addition of an angiotensin-
converting enzyme inhibitor with or without a thiazide
diuretic may reduce the edema associated with dihydropyr-
idine calcium channel blockers. To the extent that “vaso-
dilatory” edema also occurs with TZDs, this strategy may
be helpful.49,50 In this situation also, the dose of TZD might
be lowered or alternative drugs to control glycemia
instituted.
● If a new diagnosis of CHF is made or considered likely,
even in the absence of prior left ventricular dysfunction, the
use of the TZD should be reconsidered. Dosage change and
temporary or permanent discontinuance are the obvious
options, but no one of these is preferred for all patients.
Treatment directed to CHF should be initiated according to
current guidelines.51 In the absence of systolic dysfunction,
only diuretics such as furosemide may be necessary. The
duration of diuretic therapy can be quite variable, as the
need for diuresis may be temporary if the patient improves
Risk Factors for Heart Failure in Patients Treated With TZDs
1. History of heart failure (either systolic or diastolic)
2. History of prior myocardial infarction or symptomatic coronary artery
disease
3. Hypertension
4. Left ventricular hypertrophy
5. Significant aortic or mitral valve heart disease
6. Advanced age (70 years)
7. Long-standing diabetes (10 years)
8. Preexisting edema or current treatment with loop diuretics
9. Development of edema or weight gain on TZD therapy
10. Insulin coadministration
11. Chronic renal failure (creatinine 2.0 mg/dL)
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and fluid retention disappears with the discontinuation of
the TZD.
● For patients with known left ventricular dysfunction who
develop CHF while on a TZD, the drug should be discon-
tinued, and therapy with diuretics, angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers,
-blockers, and digoxin should be considered and titrated
according to the severity of the patient’s condition and
current treatment guidelines for CHF.
Conclusions
The primary treatment goal in type 2 diabetes is restoration
and maintenance of normoglycemia and the prevention of
CVD. The range of therapeutic options has been extended
with the introduction of TZDs used as monotherapy or in
combination with oral hypoglycemic drugs or insulin. There
is substantial interest in whether these agents may reduce or
modify risk of CVD through a wide range of peroxisome
proliferator–activated receptor-–mediated effects on the car-
diovascular system, in addition to their recognized efficacy as
glucose-lowering drugs to treat type 2 diabetes.6,7
Edema is a recognized side effect of these drugs, particu-
larly when combined with insulin. Both patients and health-
care providers should be cognizant of the risk of CHF when
TZDs are used in patients with type 2 diabetes. Prospective
clinical trials are currently underway to ascertain the cardio-
vascular safety of TZDs in patients with diabetes and under-
lying heart disease.
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